Responses
Regular and young investigator award abstracts
Novel single-agent immunotherapies
685 A highly selective and potent HPK1 inhibitor enhances immune cell activation and induces robust tumor growth inhibition in a murine syngeneic tumor model
Compose a Response to This Article
Other responses
No responses have been published for this article.
